![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 20, 16674-16682, May 18, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of A full-length and C-terminally truncated version
of human endogenous retrovirus (HERV)-K10 protease were
expressed in Escherichia coli and purified to homogeneity.
Both versions of the protease efficiently processed HERV-K10 Gag
polyprotein substrate. HERV-K10 Gag was also cleaved by human
immunodeficiency virus, type 1 (HIV-1) protease, although at different
sites. To identify compounds that could inhibit protein processing
dependent on the HERV-K10 protease, a series of cyclic ureas that had
previously been shown to inhibit HIV-1 protease was tested. Several
symmetric bisamides acted as very potent inhibitors of both the
truncated and full-length form of HERV-K10 protease, in subnanomolar or
nanomolar range, respectively. One of the cyclic ureas, SD146, can
inhibit the processing of in vitro translated HERV-K10 Gag
polyprotein substrate by HERV-K10 protease. In addition, in virus-like
particles isolated from the teratocarcinoma cell line NCCIT, there is
significant accumulation of Gag and Gag-Pol precursors upon treatment
with SD146, suggesting the compound efficiently blocks HERV-K Gag
processing in cells. This is the first report of an inhibitor able to
block cell-associated processing of Gag polypeptides of an endogenous retrovirus.
Inhibition of Human Endogenous Retrovirus-K10 Protease in
Cell-free and Cell-based Assays*
§,
,
,
**, and
§§
Virology and ¶ Chemical
and Physical Sciences, Experimental Station, DuPont Pharmaceuticals,
Wilmington, Delaware 19880 and the
Protein Chemistry Laboratory,
SAIC Frederick, NCI-Frederick Cancer Research and Development
Center, National Institutes of Health, Frederick, Maryland 21702
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.

Present address: Lilly Research Labs. Indianapolis, IN 46285.
§§
To whom correspondence should be addressed: DuPont
Pharmaceuticals, Dept. of Virology, Experimental Station E336/22, P.O. Box 80336, Wilmington, DE 19880-0336. Tel.: 302-695-9493; Fax: 302-695-9420; E-mail: bruce.d.korant@dupontpharma.com.
This article has been cited by other articles:
![]() |
J. H. Blusch, S. Seelmeir, and K. von der Helm Molecular and Enzymatic Characterization of the Porcine Endogenous Retrovirus Protease J. Virol., June 27, 2002; 76(15): 7913 - 7917. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |